AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company is working to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (“RCC”). The Company has sublicensed tivozanib (FOTIVDA®) for oncological indications in Europe and other territories outside of North America. Tivozanib is approved in the European Union, as well as Norway and Iceland, for the first-line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC. The Company also has other product candidates in pre-clinical or clinical development for oncology, age-related macular degeneration and cancer cachexia.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that Mike Ferraresso , Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced two poster presentations at the upcoming American Society of Clinical Oncology ( ASCO ) Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois .
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- AVEO Oncology (NASDAQ: AVEO ) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “With a successful recent equity offering, together with the triggering of a FOTIVDA ® (tivozanib) milestone